

Georgia Bio Legislative Report February 23, 2018 Days 23-26 of 40 Day Session

General Update:

The General Assembly met this week for days 23-26. Please <u>click here</u> for a copy of the adjournment resolution.

The House and Senate had a very busy week of committee hearings preparing for Crossover Day next Wednesday, February 28. The 28th day of the 40-day session is known as Crossover Day and is the last day a bill can move from one chamber to the other. Bills that don't meet the crossover deadline are "dead" but language can still be amended onto bills that did move as long as subject matter is germane.

Bill Movement

HB 519- Insurance; health benefit plans; utilize certain clinical review criteria to establish step therapy protocols

Bill Author: Rep. Sharon Cooper-R Marietta

Bill Status: 2/23/2018 Passed House Insurance Committee; House Rules

HB 519 passed by substitute both the Life and Health subcommittee of House Insurance and the full House Insurance Committee this week. The current version of HB 519 is a compromise from all parties involved and establishes a process for when it is medically appropriate to override a step therapy protocol for patients.

Georgia Bio Position: SUPPORT

HB 769 Health; recommendations from the House Rural Development Council

Rep. Rick Jasperse (R Jasper)

Bill Status: 2/21/2018-Passed House; Senate Health and Human Services

HB 769 is a product of recommendations made by the House Rural Development Council. This bill passed House on Wednesday and will move over to the Senate for consideration. It establishes the Rural Center for Health Care Innovation and Sustainability which will conduct research to identify a postsecondary institution to educate leadership in hospitals to conduct business better. It revises provisions that dictate how pharmacists distribute medications in rural Georgia. HB 769 also streamlines and expedites the billing process for state medical plans.

Georgia Bio Position: Monitoring

Bills of Interest

HB 747- Medical assistance; Medicaid recipients receive unrestricted access to hemophilia medications

Bill Author: Rep. Sharon Cooper-R Marietta Bill Status: House Health and Human Services

HB 747 would provide that Medicaid recipients have unrestricted access to medications prescribed for hemophilia by prohibiting preferred drug list, prior 12 authorization, step edit, or other drug management requirements on any such medications approved by the Federal Food and Drug Administration.

Georgia Bio Position: SUPPORT

HB 873- Prescription Drug Benefits Freedom of Information and Consumer Protection Act

Bill Author: David Knight-R Griffin Bill Status: House Insurance

HB 873 would provide consumer protections and freedom of information regarding prescription drug benefits. HB 873 was introduced on behalf of the Medical Association of Georgia and it requires that PBMs and insurers use a standard prior authorization form developed by the DOI with input from a committee of physicians and insurers. Further, it requires that PBMs/insurers include on their websites formulary information as well as processes for step therapy requirements.

Georgia Bio Position: Monitoring

SB 357-The Health Act

Bill Sponsor: Senator Dean Burke-R Bainbridge

Bill Status: Passed Senate 2/7/2018; House Health and Human Services

SB 357 would establish a new Health Coordination and Innovation Council made of public and private healthcare

institutions that would be charged with advising on best practices in healthcare for the state.

Georgia Bio Position: Monitoring

SB 352-Commission on Substance Abuse and Recovery

Bill Sponsor: Renee Unterman-R Buford

Bill Status: Passed Senate 2/7/2018; House Health and Human Services

SB 352 would create the Commission on Substance Abuse and Recovery to help combat the issue of opioid addiction in

Georgia.

Georgia Bio Position: Monitoring

SB 432 'Georgia Tax Credit Business Case Act'

Sen. John Albers (R Roswell)

Bill Status: 2/21/2018 Passed Senate Finance; Senate Rules

Senate Bill 432 seeks to repeal thirty-five (35) separate exemptions from state sales and use taxes over a phased period ranging from December 31, 2019 to December 31, 2025 including exemptions related to prescription drugs and medical equipment.

Georgia Bio Position: Monitoring

GABIO POLICY & ADVOCACY COMM. MEETINGS/CALL SCHEDULE FOR 2018 GA LEGISLATIVE SESSION

Mon. Feb. 26 at 12 pm Mon. Mar. 5 at 12pm Mon. Mar. 19 at 12pm Mon. April 2 at 12pm